Analisi molecolare della malattia midollare ed ematica in pazienti affetti da neuroblastoma

Translated title of the contribution: Molecular analysis of minimal residual disease in bone marrow and blood from neuroblastoma patients

M. V. Corrias, P. Scaruffi, M. Occhino, V. Pistoia

Research output: Contribution to journalArticle

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Prognosis for patients with metastatic NB remains grim due to the achievement of remissions of short duration followed by lethal tumor recurrence. Contributory factors to the latter event are the persistence of malignant cells in the bone marrow and, possibly, the reinfusion of tumor cells present in blood aphereses administered to the patients to reconstitute the hematopoietic system following high dose chemotherapy. The methods presently used to detect minimal residual disease, i.e. the neoplastic cells that persist in the host following treatment, are of limited sensitivity. Thus, novel highly sensitive and specific techniques are warranted. Molecular analysis by RT-PCR may be one of these techniques. Thus, the genes coding for tyrosine hydroxylase (TH) and pgp9.5 are expressed in nueroblastoma cells but not in hematopoietic cells. In 1997, we have started a study aimed at comparing different methods for the analysis of tumor cell contamination in the bone marrow and in the peripheral blood. Our results indicate that molecular techniques are superior to other methodologies as for the detection of malignant neuroblasts i) in the peripheral blood and aphereses and ii) in the bone marrow, either during or after chemotherapy administration. We are now defining the best experimental conditions to apply the real-time PCR technology to quantitative investigation of minimal residual disease in NB.

Original languageItalian
Pages (from-to)21-27
Number of pages7
JournalGaslini
Volume33
Issue number1
Publication statusPublished - 2001

Fingerprint

Residual Neoplasm
Neuroblastoma
Bone Marrow
Blood Component Removal
Neoplasms
Hematopoietic System
Drug Therapy
Tyrosine 3-Monooxygenase
Bone Marrow Cells
Real-Time Polymerase Chain Reaction
Technology
Recurrence
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Analisi molecolare della malattia midollare ed ematica in pazienti affetti da neuroblastoma. / Corrias, M. V.; Scaruffi, P.; Occhino, M.; Pistoia, V.

In: Gaslini, Vol. 33, No. 1, 2001, p. 21-27.

Research output: Contribution to journalArticle

@article{9407bda310054cde94cb0b34fd5842e7,
title = "Analisi molecolare della malattia midollare ed ematica in pazienti affetti da neuroblastoma",
abstract = "Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Prognosis for patients with metastatic NB remains grim due to the achievement of remissions of short duration followed by lethal tumor recurrence. Contributory factors to the latter event are the persistence of malignant cells in the bone marrow and, possibly, the reinfusion of tumor cells present in blood aphereses administered to the patients to reconstitute the hematopoietic system following high dose chemotherapy. The methods presently used to detect minimal residual disease, i.e. the neoplastic cells that persist in the host following treatment, are of limited sensitivity. Thus, novel highly sensitive and specific techniques are warranted. Molecular analysis by RT-PCR may be one of these techniques. Thus, the genes coding for tyrosine hydroxylase (TH) and pgp9.5 are expressed in nueroblastoma cells but not in hematopoietic cells. In 1997, we have started a study aimed at comparing different methods for the analysis of tumor cell contamination in the bone marrow and in the peripheral blood. Our results indicate that molecular techniques are superior to other methodologies as for the detection of malignant neuroblasts i) in the peripheral blood and aphereses and ii) in the bone marrow, either during or after chemotherapy administration. We are now defining the best experimental conditions to apply the real-time PCR technology to quantitative investigation of minimal residual disease in NB.",
keywords = "Minimal residual disease, Neuroblastoma, RT-PCR",
author = "Corrias, {M. V.} and P. Scaruffi and M. Occhino and V. Pistoia",
year = "2001",
language = "Italian",
volume = "33",
pages = "21--27",
journal = "Gaslini",
issn = "0390-5845",
publisher = "Masson SpA",
number = "1",

}

TY - JOUR

T1 - Analisi molecolare della malattia midollare ed ematica in pazienti affetti da neuroblastoma

AU - Corrias, M. V.

AU - Scaruffi, P.

AU - Occhino, M.

AU - Pistoia, V.

PY - 2001

Y1 - 2001

N2 - Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Prognosis for patients with metastatic NB remains grim due to the achievement of remissions of short duration followed by lethal tumor recurrence. Contributory factors to the latter event are the persistence of malignant cells in the bone marrow and, possibly, the reinfusion of tumor cells present in blood aphereses administered to the patients to reconstitute the hematopoietic system following high dose chemotherapy. The methods presently used to detect minimal residual disease, i.e. the neoplastic cells that persist in the host following treatment, are of limited sensitivity. Thus, novel highly sensitive and specific techniques are warranted. Molecular analysis by RT-PCR may be one of these techniques. Thus, the genes coding for tyrosine hydroxylase (TH) and pgp9.5 are expressed in nueroblastoma cells but not in hematopoietic cells. In 1997, we have started a study aimed at comparing different methods for the analysis of tumor cell contamination in the bone marrow and in the peripheral blood. Our results indicate that molecular techniques are superior to other methodologies as for the detection of malignant neuroblasts i) in the peripheral blood and aphereses and ii) in the bone marrow, either during or after chemotherapy administration. We are now defining the best experimental conditions to apply the real-time PCR technology to quantitative investigation of minimal residual disease in NB.

AB - Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Prognosis for patients with metastatic NB remains grim due to the achievement of remissions of short duration followed by lethal tumor recurrence. Contributory factors to the latter event are the persistence of malignant cells in the bone marrow and, possibly, the reinfusion of tumor cells present in blood aphereses administered to the patients to reconstitute the hematopoietic system following high dose chemotherapy. The methods presently used to detect minimal residual disease, i.e. the neoplastic cells that persist in the host following treatment, are of limited sensitivity. Thus, novel highly sensitive and specific techniques are warranted. Molecular analysis by RT-PCR may be one of these techniques. Thus, the genes coding for tyrosine hydroxylase (TH) and pgp9.5 are expressed in nueroblastoma cells but not in hematopoietic cells. In 1997, we have started a study aimed at comparing different methods for the analysis of tumor cell contamination in the bone marrow and in the peripheral blood. Our results indicate that molecular techniques are superior to other methodologies as for the detection of malignant neuroblasts i) in the peripheral blood and aphereses and ii) in the bone marrow, either during or after chemotherapy administration. We are now defining the best experimental conditions to apply the real-time PCR technology to quantitative investigation of minimal residual disease in NB.

KW - Minimal residual disease

KW - Neuroblastoma

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0034976354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034976354&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0034976354

VL - 33

SP - 21

EP - 27

JO - Gaslini

JF - Gaslini

SN - 0390-5845

IS - 1

ER -